Lilly, Nektar to co-develop new immunotherapy – PharmaTimes
PharmaTimes |
Lilly, Nektar to co-develop new immunotherapy
PharmaTimes Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter's experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million. NKTR-358 is a potential … Nektar Therapeutics – NKTR – Stock Price Today – Zacks |
